Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
TBPH Analyst Ratings
Moderate Buy
3 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TBPH Stock 12 Month Forecast
Average Price Target
$17.83
▲(28.46% Upside)
| Highest Price Target$26.00 | Average Price Target$17.83 | Lowest Price Target$13.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$25
Buy
80.12%
Upside
Reiterated
08/25/25
Promising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial DevelopmentsWe continue to view CYPRESS as significantly de- risked by preceding Phase 3 results from Study 0170 where ampreloxetine showed positive trends on OHSA composite score and on individual items on symptom scales without worsening of supine hypertension. Both approved Tx options for nOH carry boxed warnings for supine hypertension, so we expect the absence of this risk with ampreloxetine to emerge as an important point of differentiation. If CYPRESS confirms the benefit seen with ampreloxetine in Study 0170, Dr. Horacio Kaufmann (Professor of at NYU Medicine) indicated intent to prescribe ampreloxetine to "the majority" of his patients with nOH due to MSA.
JonesTrading
$26
Buy
87.32%
Upside
Reiterated
08/25/25
TR | OpenAI - 4o
$14.5→$15
Hold
8.07%
Upside
Reiterated
08/25/25
H.C. Wainwright
$15
Buy
8.07%
Upside
Reiterated
08/13/25
Leerink Partners
$10→$13
Hold
-6.34%
Downside
Reiterated
08/13/25
TD Cowen
$12→$13
Hold
-6.34%
Downside
Reiterated
08/13/25
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty1:48 AM THERAVANCE BIOPHARMA (NASDAQ: TBPH) Hold (2) ESG $13.00 (Prior $12.00) REPORTS Q2; YUPELRI REV STRONG, CYPRESS ENROLLMENT TO COMPLETE IN ~WEEKS THE TD COWEN INSIGHT TBPH reported Q2 Yupelri collaboration revenue of $18.7MM vs. $16MME consensus on Yupelri sales of $66.3MM. in proceeds from Trelegy royalty sale and a milestone payment of $7.5MM from Yupelri approval in China, this led to net income of $55MM. Trelegy appears on track to max out '25-'26 milestones. Ampreloxetine's Ph3 enrollment to complete by late summer (i.e. data in H1:26). Viatris reported net Yupelri sales of $66.3MM in Y/Y) resulting in $18.7MM (+21% in reported revenue to Theravance.
Evercore ISI
$11
Hold
-20.75%
Downside
Assigned
11/13/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$25
Buy
80.12%
Upside
Reiterated
08/25/25
Promising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial DevelopmentsWe continue to view CYPRESS as significantly de- risked by preceding Phase 3 results from Study 0170 where ampreloxetine showed positive trends on OHSA composite score and on individual items on symptom scales without worsening of supine hypertension. Both approved Tx options for nOH carry boxed warnings for supine hypertension, so we expect the absence of this risk with ampreloxetine to emerge as an important point of differentiation. If CYPRESS confirms the benefit seen with ampreloxetine in Study 0170, Dr. Horacio Kaufmann (Professor of at NYU Medicine) indicated intent to prescribe ampreloxetine to "the majority" of his patients with nOH due to MSA.
JonesTrading
$26
Buy
87.32%
Upside
Reiterated
08/25/25
TR | OpenAI - 4o
$14.5→$15
Hold
8.07%
Upside
Reiterated
08/25/25
H.C. Wainwright
$15
Buy
8.07%
Upside
Reiterated
08/13/25
Leerink Partners
$10→$13
Hold
-6.34%
Downside
Reiterated
08/13/25
TD Cowen
$12→$13
Hold
-6.34%
Downside
Reiterated
08/13/25
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty1:48 AM THERAVANCE BIOPHARMA (NASDAQ: TBPH) Hold (2) ESG $13.00 (Prior $12.00) REPORTS Q2; YUPELRI REV STRONG, CYPRESS ENROLLMENT TO COMPLETE IN ~WEEKS THE TD COWEN INSIGHT TBPH reported Q2 Yupelri collaboration revenue of $18.7MM vs. $16MME consensus on Yupelri sales of $66.3MM. in proceeds from Trelegy royalty sale and a milestone payment of $7.5MM from Yupelri approval in China, this led to net income of $55MM. Trelegy appears on track to max out '25-'26 milestones. Ampreloxetine's Ph3 enrollment to complete by late summer (i.e. data in H1:26). Viatris reported net Yupelri sales of $66.3MM in Y/Y) resulting in $18.7MM (+21% in reported revenue to Theravance.
Evercore ISI
$11
Hold
-20.75%
Downside
Assigned
11/13/24
Best Analysts Covering Theravance Biopharma
1 Month
xxx
Success Rate
10/15 ratings generated profit
Average Return
+2.12%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.12% per trade.
3 Months
xxx
Success Rate
9/15 ratings generated profit
Average Return
+2.29%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.29% per trade.
1 Year
Success Rate
7/15 ratings generated profit
Average Return
+13.58%
reiterated a buy rating 20 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +13.58% per trade.
2 Years
xxx
Success Rate
12/15 ratings generated profit
Average Return
+30.51%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +30.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TBPH Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Aug 25
Strong Buy
1
1
3
7
12
Buy
0
0
0
0
1
Hold
10
7
10
15
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
8
13
22
31
Each month's total comprises the sum of three months' worth of ratings.
TBPH Financial Forecast
TBPH Stock Forecast FAQ
What is TBPH’s average 12-month price target, according to analysts?
Based on analyst ratings, Theravance Biopharma’s 12-month average price target is 17.83.
What is TBPH’s upside potential, based on the analysts’ average price target?
Theravance Biopharma has 28.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TBPH a Buy, Sell or Hold?
Theravance Biopharma has a consensus rating of Moderate Buy which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
What is Theravance Biopharma’s price target?
The average price target for Theravance Biopharma is 17.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $13.00. The average price target represents 28.46% Increase from the current price of $13.88.
The highest analyst price target is $26.00 ,the lowest forecast is $13.00. The average price target represents 28.46% Increase from the current price of $13.88.
What do analysts say about Theravance Biopharma?
Theravance Biopharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of TBPH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.